In the current study, we depict an individual with gastric cancer that harbored EGFR as well as MDM2 amplification who had indolent disease; the patient, however, showed explosive progression after being given the anti–PD-1 inhibitor nivolumab (Fig 4). Here, EGFR is linked to gastric cancer.